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Large granular lymphocytic (LGL) leukemia is an uncommon clonal lymphoproliferative disorder.
Lambert–Eaton Myasthenic Syndrome (LEMS) is a rare neuromuscular autoimmune disease caused by
pathogenic autoantibodies targeting the voltage-gated calcium channels (VGCC) on the presynaptic
nerve terminal. We here describe the case of a 77-year old patient with LGL leukemia, associated with a
seropositive and symptomatic LEMS and a seronegative rheumatoid arthritis. LGL leukemia treatment
clearly improved LEMS symptoms, and led to anti-VGCC antibodies value decrease. To our knowledge,
this is the ﬁrst ever described association between LGL leukemia and LEMS.
& 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Large granular lymphocytic (LGL) leukemia is an uncommon
clonal lymphoproliferative disorder, which has usually an indo-
lent clinical behavior and can be associated, at diagnosis or during
evolution, with a variety of autoimmune disorders including
autoimmune cytopenias such as pure red cell aplasia, Sjogrens
syndrome and rheumatoid arthritis (RA).1 Lambert–Eaton
Myasthenic Syndrome (LEMS) is a rare neuromuscular autoim-
mune disease caused by pathogenic autoantibodies targeting the
voltage-gated calcium channels (VGCC) on the presynaptic nerve
terminal. It traduces by muscular weakness and autonomic
dysfunction. It is strongly associated with Lung Small Cell Carci-
noma (LSLC), and fulﬁlls the paraneoplastic syndrome deﬁnition
criteria.2 We here report on a patient with LGL leukemia,
associated with a seropositive and symptomatic LEMS and a
seronegative rheumatoid arthritis.2. Observation
A 77 year-old male without any relevant medical history nor
professional toxic exposition, presented in 2001 with a permanentue et de The´rapie Cellulaire,
ie Aubrac, 63100
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-NC-ND license.cough (without detectable infectious etiology), proximal muscular
weakness, unusual asthenia, and a dry mouth sensation. Clinical
examination showed a complete areﬂexia. Paraclinical explorations
showed anti N-type autoantibodies directed against VGCC strongly
positives (390 pmol/l; Nlo100), without anti-P/Q type VGCC anti-
bodies. Laboratory tests showed a normal blood cells differential
count. Neurophysiological tests showed a trend to lower ﬁrst
compound muscle action potential amplitude, with a discrete
post-exercise increment, which were compatible with LEMS.
An exhaustive neoplastic screening was performed, showing an
asymptomatic and non-capsule disrupting prostatic adenocarcinoma.
Patient was effectively treated by hormonotherapy, leading to nor-
malization of PSA-value, but without effect on patient’s neurological
symptoms. Anti N-type VGCC-directed autoantibodies-value contin-
ued to increase (530 pmol l1 at maximum). Six months later, patient
presented clinical features compatible with active rheumatoid arthri-
tis (RA) (tenosynovitis and arthritis). Laboratory tests showed a
moderate hyperlymphocytosis (4.6109/l), predominantly composed
of LGL. LGL phenotypic expression was CD3þ , CD5low, CD7low,
CD8þ , CD4low, CD16þ , CD57þ , CD56 and TCRab gene rearran-
gement showed a monoclonal pattern. Patient was neutropenic
(PMN: 0.8109/l). Serum protein electrophoresis did not show hypo-
nor hyper-gammaglobulinemia. C-reactive protein value was below
5mg/l. Autoantibodies screening showed negativity for Rheumatoid
Factor, antikeratin antibodies and antinuclear antibodies, and posi-
tivity for antiphospholipid antibody. The patient was treated with
steroids (initially 15 mg/day) and methotrexate (7.5 mg/m2/week).
Clinical manifestations of RA and of neurological symptoms were
R. Lemal et al. / Leukemia Research Reports 2 (2013) 32–33 33quickly and dramatically improved. This ﬁrst-line therapy was
continued indeﬁnitely, with a steroid-dependence at 6 mg/day
regarding rheumatological manifestations, and without any neurolo-
gical relapse. The patient achieved a complete and persistent hema-
tological response within 10 months. Partial molecular response was
documented with a persistence of 10% of clonal TCRab using PCR.
The anti-N type autoantibodies against VGCC-value progressively
decreased (310 pmol l1 at minimum, 11 months after beginning
the LGL leukemia treatment; anti-N antibodies assay was never
repeated after this date). Neither Lung Small-Cell Carcinoma (LSCC),
nor other preexistent carcinomawas detected during the next 9-years
follow-up. Finally, the patient died in 2011, 9 years later, at the age of
86 years, due to a brain tumor without any evidence of RA/LGL
leukemia nor LEMS relapse.3. Discussion
This observation reports an unusual association of LEMS with
LGL leukemia occurring in the same patient, and clearly shows
that both diseases beneﬁted from LGL leukemia therapy. Metho-
trexate and steroids rapidly induced hematological complete
remission associated with disappearance of RA and neurological
symptoms. Anti-N antibodies titers progressively decreased.
Indeed, correlations have already been shown between the anti-
N titer evolution and the disease activity in longitudinal studies
on single patients.3
Moreover, patient did not display any resurgence of LEMS over
the time. This observation supports the hypothesis that LEMS
could be considered as a paraneoplastic manifestation of LGL
leukemia. Since T-regulatory cells protein expression pattern had
been shown to be different in some LEMS patients,4 we can
hypothesize that LEMS occurrence could be linked to a speciﬁc
immunoregulatory system deregulation in the context of LGL
leukemia. To our knowledge, this is the ﬁrst ever described
association of LEMS with LGL leukemia, whereas it has been
reported in other lymphoproliferative diseases5 such as multiple
myeloma,6 Hodgkin lymphoma,7 or even in myeloproliferative
ones, such as chronic myeloid leukemia.8
About half of the patients presenting with LEMS have a SCLC.
For 94% of these patients, LEMS manifestations are usually
present 6 months before the SCLC diagnosis.9 Our patient under-
went regular chest CT scan which were always non-contributive.
He did not develop any pulmonary symptoms over the 9 years
following LEMS diagnosis.
LEMS has been described in association with at least 6 cases of
prostatic carcinoma,2,10–12 which all had some neuroendocrine
and/or small cells features. In our patient, histopathology con-
cludes to a localized adenocarcinoma, without any neuroendo-
crine or small cell feature. Hormonotherapy was efﬁcacious onthe PSA-value, improving neither LEMS manifestations nor anti-N
VGCC antibodies values. Anti-N antibodies value even increased.
Prostate irradiation was performed with good efﬁcacy on
PSA-value, without any impact on the LEMS.
The patient ﬁnally died in March 2011 from a cerebral tumor,
which had radiological features and quick progression time
arguing for its glioblastoma nature. No histological documenta-
tion was performed. The long term interval (9 years) between
LEMS manifestations and the late onset of brain tumor, suggests
that glioblastoma was not linked to LEMS.
LEMS may be difﬁcult to diagnose, and neurological symptoms
can be masked or under evaluated in patients having rheumatoid
symptoms as it is observed in LGL leukemia. A strict neurological
clinical evaluation, completed with systematic electromyography
or/and anti-VGCC antibodies assay should be done in this setting.
We also suggest that careful examination of blood smears and
immunophenotype should be performed for patients having LEMS
without evident underlying neoplastic disease.References
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